Asaf Danziger serves as the CEO of NovoCure, a company focused on innovative cancer treatments. With an MBA from a respected business school, he’s been leading the company since January 2019. Danziger is known for having a big role in...

Asaf Danziger serves as the CEO of NovoCure, a company focused on innovative cancer treatments. With an MBA from a respected business school, he’s been leading the company since January 2019. Danziger is known for having a big role in helping the company aim to expand its oncology business and run vital clinical studies. Interestingly, he hasn’t received stock options or grants since 2021, showing a different approach in his compensation structure aiming to align his interests with senior management. In 2023, his total compensation was about $1.5 million, which included his salary and a substantial bonus tied to performance. His focus is on important corporate goals related to patients in clinical trials. Under his leadership, NovoCure has been working towards big achievements like obtaining FDA approvals for new treatments. Asaf was born in 1973 and brings a wealth of experience to the company, shaping it for future growth.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

N

Asaf Danziger

CEO of NovoCure

Education

MBA from Tel Aviv University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

May 15, 1966 - 59 years ago

CEO of NovoCure for

23 years 5 months (Jan 2002 - Present)

Previous Experience

CEO of various technology companies

Rivals

Competitors/colleagues of Asaf Danziger

Holdings

See how much did Asaf Danziger make over time.

Danziger's holdings reflect his long-term commitment to NovoCure, showing a strategic focus on aligning his interests with the business's success. He had a peak in his wealth due to stock options in previous years, notably when NovoCure was performing well....

Danziger's holdings reflect his long-term commitment to NovoCure, showing a strategic focus on aligning his interests with the business's success. He had a peak in his wealth due to stock options in previous years, notably when NovoCure was performing well. However, a significant shift occurred as he received no stock grants or options from 2021 onwards, demonstrating a shift towards paying himself based on direct performance measures rather than stock-related bonuses. His current holdings are centered around NovoCure's stock, which is crucial to the company's growth strategy. This move suggests a more conservative approach, prioritizing stability over speculative gains, especially as the company navigates critical phases in its clinical trials.

Insider Trading

See recent insider trades of Asaf Danziger.

No insider trades found for this CEO.

Compensation History

See how much did Asaf Danziger make over time.

In 2023, Asaf Danziger earned a total compensation of approximately $1.5 million from NovoCure. His salary was about $756,093, with a notable annual bonus of $507,742 tied to performance metrics. Unlike previous years, he did not receive stock options or equity grants, marking a departure from traditional compensation structures. His bonus was closely linked to achieving corporate objectives, emphasizing results over guaranteed payouts. The company has a philosophy that links executive pay to performance, pushing for alignment with shareholder interests. This reflects an interesting trend in executive compensation where long-term value creation is prioritized over short-term gains. It paints a picture of a leader focused on building sustainable growth rather than quick financial wins.

Year

2023

Total Compensation

$1.52M

Salary

$756.09K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate executives, aligning their interests with those of shareholders through performance-based compensation.

Bonus

$507.74K

Board Justification

The annual incentive bonus for 2023 was based on the achievement of predetermined corporate objectives, resulting in a payout of 89% of the target bonus.

Other

$257.19K

Board Justification

Includes contributions to benefits, vacation payout, and other compensation.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was granted or vested in 2023 as the CEO did not receive any equity awards for the year.

Performance Metrics

The performance metrics for determining the compensation included corporate objectives related to patient starts, clinical trial milestones, and financial performance.